

ACF IMT Programme Details in conjunction with the University of Manchester

Recruitment to posts starting in August 2022

Post availability

There is one post available in either Medical Oncology or Clinical Oncology

- Medical Oncology – You can apply at ST1 level in this round of recruitment.
- Clinical Oncology – You can apply at ST3 level in this round of recruitment.
- Histopathology- You can apply at ST1 level in this round of recruitment.

Please note if you are appointed at ST1 or ST2 level, you will be placed in an appropriate Core Medical Training track until you reach ST3 level.

Overview

You can find generic information about Academic Clinical Fellowships in the North West plus links to the National Institute for Health Research's guidance via <https://www.nwpgmd.nhs.uk/nihr-academic-clinical-fellowships-glance>

Research Areas / Research Environment

The Christie Cancer Centre

The Christie Hospital and Holt Radium Institute moved to the present Withington site in 1932 and has grown to be the largest single site cancer hospital in the United Kingdom serving a population of 3.2 million. The Christie has been designated as a separate teaching hospital of the University of Manchester. Along with the Paterson Institute for Cancer Research and North Western Regional Medical Physics Department, it formed the Christie Hospital NHS Trust in 1991. The hospital was awarded Foundation Trust status in 2007.

The Christie has clinical groups specialising in Clinical Oncology, Medical Oncology, Haematology, Palliative Medicine, Surgical Oncology, Paediatric and Adolescent Oncology, Endocrinology, Psychological Medicine and Clinical Genetics, Radiology and Pathology. All consultants are site specialised and common treatment policies are developed by multidisciplinary Disease Groups (DGs). There is a Haematology Transplant Unit and a Critical Care Unit on site.

The trust also has clinical groups specialising in Palliative Medicine, Surgical Oncology, Paediatric and Adolescent Oncology, Endocrinology, Psychological Medicine and Clinical Genetics.

The trust has dedicated Histopathology, Haematology, Biochemistry and Diagnostic Radiology Departments including access to on-site PET-CT. The Radiotherapy Department has access to SABR, adaptive radiotherapy and MR-LINAC and the Proton Beam Therapy centre, the first NHS facility in the UK was opened in 2019.

The trust has a Clinical Outcomes Unit, which specialises in Trust outcome data and offers support clinical studies and trials. The trust has a specific intranet with IT support. The trust has a Medical Library staffed by professional librarians offering a range of services including a modern journal collection, extensive book library and on line search facilities.

The Christie NHS Foundation Trust is committed to cancer research. A new Clinical Trials and Chemotherapy wing opened in 2010. More than 97,000 chemotherapy treatments were delivered in 2019.

Over 650 clinical research studies were active in 2019 and work on the Paterson redevelopment, a £150 million purpose-built biomedical research facility that will co-locate clinical and basic/ translational scientists is planned to complete in 2023.

The Trust has an innovative Experimental Cancer Medicine team who deliver a cutting edge portfolio of early phase trials and are internationally recognised for their work in biomarker-led patient selection for phase I trial entry. There is also an active adaptive T-cell therapy programme embedded within the Innovate Manchester Advanced Therapy Centre Hub based at The Christie.

Medical Oncology Training and Research Environment

The specialty trainee in medical oncology (48 months) will be part of the Health Education England training rotation. The post holder will be based at The Christie for just over 3 years; for up to one year the trainee will be based at either Preston or Lancaster. The successful applicant would be expected to work alongside consultants and trainees in out-patient clinics, supervising chemotherapy delivery and performing on-treatment reviews and follow-up assessments. There is a requirement for resident on-call commitment, the rota pattern is currently 1 in 11 however this is flexible between 1 in 10 and 1 in 14 dependant on requirement. There is a 1B supplement currently payable for on-call commitments.

The Department of Medical Oncology participates in the clinical undergraduate teaching programme of the University of Manchester and students visit the trust for seminar, outpatients and bedside teaching at different stages in their training.

There are dedicated courses designed for postgraduate students training in Oncology. Consultants are expected to participate in the specialist registrar and F2 teaching programme.

Post-graduate training (ST3 onwards) is co-ordinated by Dr Laura Cove-Smith and Dr Laura Horsley for Medical Oncology and Dr J Coote for Clinical Oncology. There is a joint Medical Oncology Teaching Programme with Clatterbridge Oncology Centre with bimonthly meetings that follow a rotating timetable which cover the Medical Oncology curriculum. In addition, there is a Medical Oncology Fellows training programme and an active School of Oncology which provide additional educational opportunities.

The Systemic Therapy Research Group represents and supports research-active clinicians within the Dept of Medical Oncology. It meets weekly with the aim of providing a supportive environment to discuss, develop and deliver research ideas. Specialist Trainees and Fellows are encouraged to participate in these meetings.

Medical oncology aspirants are encouraged and required to get in touch with Dr Laura Cove-Smith, Dr Laura Horsley or Dr Andrew Clamp to signpost trainees to available research prospects, opportunities and collaborators within Medical Oncology. Medical oncology trainees will be encouraged to go out of programme to pursue a PhD or MD in their chosen field of interest. There are a number of consultants within Medical Oncology with extensive research portfolio and the candidate would be advised to liaise with them at an early stage

Other Research Facilities

Attached to the Trust in the Manchester Cancer Research Centre (MCRC) Oglesby Cancer Research Building (Director – Professor Rob Bristow). Established in 2006, the MCRC is a partnership between the Christie, Cancer Research UK and The University of Manchester acts as a resource multiplier to drive forward cancer research in Manchester with the goal of becoming one of the leading 5 global comprehensive cancer centres by 2025 by developing a Team Science approach.

The £150 million Paterson redevelopment that will be completed in 2023 will bring the Cancer Research UK Manchester Institute including the Cancer Biomarkers Centre and Drug Discovery Unit back to The Christie site collocating world-leading basic and translational cancer scientists with their clinical peers in a cutting-edge Biomedical Research Facility.

Of note, in 2019 the MCRC was awarded Cancer Research UK Clinical Academic Training Programme funding to provide early career clinician scientists greater flexibility and a wider range of training options while providing highest quality development opportunities.

]

Clinical Training

You can find out more about the clinical training programmes in the North West via the following link - <https://www.nwpgmd.nhs.uk/specialty-schools>

Clinical person specifications can be found via the following link - <https://specialtytraining.hee.nhs.uk/Recruitment/Person-specifications>.

Useful Links

<https://www.oriel.nhs.uk/Web/Vacancies>

<https://www.nwpgmd.nhs.uk/nihf-academic-clinical-fellowships-glance>

<https://specialtytraining.hee.nhs.uk/Recruitment/Person-specifications>

<https://www.nwpgmd.nhs.uk/specialty-schools>

Last reviewed: 11/10/21